Lithium and venlafaxine interaction: a case of serotonin syndrome

Universidad Autónoma de Madrid, Madrid, Madrid, Spain
Journal of Clinical Pharmacy and Therapeutics (Impact Factor: 1.53). 07/2006; 31(4):397 - 400. DOI: 10.1111/j.1365-2710.2006.00745.x

ABSTRACT Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications. The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction. We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases. A 71-year-old woman developed serotonin syndrome while receiving treatment with moderate doses of lithium and venlafaxine for refractory depression. She had been taking higher doses of venlafaxine during the previous months with no significant secondary effects. Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine.

  • Journal of Clinical Pharmacy and Therapeutics 11/2007; 32(5):529-31. DOI:10.1111/j.1365-2710.2007.00830.x · 1.53 Impact Factor
  • Revue du Rhumatisme 02/2008; 75(2):162-165. DOI:10.1016/j.rhum.2007.11.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serotonin syndrome, or serotonin toxicity (ST), is a clinical condition that occurs as a result of an iatrogenic drug-induced increase in intrasynaptic serotonin levels primarily resulting in activation of serotonin(2A) receptors in the central nervous system. The severity of symptoms spans a spectrum of toxicity that correlates with the intrasynaptic serotonin concentration. Although numerous drugs have been implicated in ST, life-threatening cases generally occur only when monoamine oxidase inhibitors are combined with either selective or nonselective serotonin re-uptake inhibitors. The triad of clinical features consists of neuromuscular hyperactivity, autonomic hyperactivity and altered mental status, which may present abruptly and progress rapidly. The awareness of ST is crucial not only in avoiding the unintentional lethal combination of therapeutic drugs but also in recognizing the clinical picture when it occurs so that treatment can be promptly initiated. In this review, the pathophysiology, clinical features, implicated drugs, diagnosis and treatment of ST are discussed.
    Expert Opinion on Drug Safety 10/2008; 7(5):587-96. DOI:10.1517/14740338.7.5.587 · 2.74 Impact Factor
Show more